Editors' Note: Neuro R2 Score: Predicting High-Risk Neurologic Readmissions Within 30 Days
Citation Manager Formats
Make Comment
See Comments

This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.
In “Neuro R2 Score: Predicting High-Risk Neurologic Readmissions Within 30 Days,” Peacock et al. retrospectively reviewed the records of 4,876 neurologic admissions over a 5-year period and found that 314 (6.4%) patients were readmitted within 30 days of discharge. Predictors for readmission included the Charlson disease count (a score based on comorbid conditions), urgent or emergent admission, discharge to rehabilitation or skilled nursing facility, and diagnosis of cancer, brain tumor, or cerebrovascular disease. These were used to design and validate the Neuro R2 score to predict 30 days' readmissions. Majersik noted that this score can help neurologists predict unplanned readmissions, a quality metric monitored by the Centers for Medicare and Medicaid Services, and recommended focusing attention on reducing readmissions for patients with brain tumors and those discharged to skilled nursing facilities. Hunter was more skeptical of the benefits of this score and commented that the utility of risk stratification algorithms is limited because of implementation barriers, inaccurate predictions, and ineffective risk reduction strategies. For Peacock et al., Freeman responded that the Neuro R2 score is one of the largest multivariate models for 30-day unplanned neurologic readmissions but that it certainly would not predict (or prevent) all 30 days' unplanned neurologic readmissions. He further noted that external validation of this model, and the creation of additional models focused on neurologic patients, is needed.
In “Neuro R2 Score: Predicting High-Risk Neurologic Readmissions Within 30 Days,” Peacock et al. retrospectively reviewed the records of 4,876 neurologic admissions over a 5-year period and found that 314 (6.4%) patients were readmitted within 30 days of discharge. Predictors for readmission included the Charlson disease count (a score based on comorbid conditions), urgent or emergent admission, discharge to rehabilitation or skilled nursing facility, and diagnosis of cancer, brain tumor, or cerebrovascular disease. These were used to design and validate the Neuro R2 score to predict 30 days' readmissions. Majersik noted that this score can help neurologists predict unplanned readmissions, a quality metric monitored by the Centers for Medicare and Medicaid Services, and recommended focusing attention on reducing readmissions for patients with brain tumors and those discharged to skilled nursing facilities. Hunter was more skeptical of the benefits of this score and commented that the utility of risk stratification algorithms is limited because of implementation barriers, inaccurate predictions, and ineffective risk reduction strategies. For Peacock et al., Freeman responded that the Neuro R2 score is one of the largest multivariate models for 30-day unplanned neurologic readmissions but that it certainly would not predict (or prevent) all 30 days' unplanned neurologic readmissions. He further noted that external validation of this model, and the creation of additional models focused on neurologic patients, is needed.
Footnotes
Author disclosures are available upon request (journal{at}neurology.org).
- © 2021 American Academy of Neurology
AAN Members
We have changed the login procedure to improve access between AAN.com and the Neurology journals. If you are experiencing issues, please log out of AAN.com and clear history and cookies. (For instructions by browser, please click the instruction pages below). After clearing, choose preferred Journal and select login for AAN Members. You will be redirected to a login page where you can log in with your AAN ID number and password. When you are returned to the Journal, your name should appear at the top right of the page.
AAN Non-Member Subscribers
Purchase access
For assistance, please contact:
AAN Members (800) 879-1960 or (612) 928-6000 (International)
Non-AAN Member subscribers (800) 638-3030 or (301) 223-2300 option 3, select 1 (international)
Sign Up
Information on how to subscribe to Neurology and Neurology: Clinical Practice can be found here
Purchase
Individual access to articles is available through the Add to Cart option on the article page. Access for 1 day (from the computer you are currently using) is US$ 39.00. Pay-per-view content is for the use of the payee only, and content may not be further distributed by print or electronic means. The payee may view, download, and/or print the article for his/her personal, scholarly, research, and educational use. Distributing copies (electronic or otherwise) of the article is not allowed.
Disputes & Debates: Rapid online correspondence
NOTE: All authors' disclosures must be entered and current in our database before comments can be posted. Enter and update disclosures at http://submit.neurology.org. Exception: replies to comments concerning an article you originally authored do not require updated disclosures.
- Stay timely. Submit only on articles published within the last 8 weeks.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- 200 words maximum.
- 5 references maximum. Reference 1 must be the article on which you are commenting.
- 5 authors maximum. Exception: replies can include all original authors of the article.
- Submitted comments are subject to editing and editor review prior to posting.